Issue 50: Pharmaceutical regulatory roundup

BY DR TIM SANDLE  | 5th November 2026

 

Catch up with the latest news from around the pharmaceutical industry with issue 50 of our regulatory review, curated by Dr Tim Sandle and RSSL.

 

Contents

Section 1: European Pharmacopoeia

 

New and revised chapters

Note: Access to the European Pharmacopeia requires registration.

The following chapters have been published in edition 13.3 of the European Pharmacopeia (Ph. Eur.). These have an effective date of 1st July 2027.

A) 2.2.40. Near-Infrared spectroscopy (revised)

Near-Infrared (NIR) spectroscopy is an analytical technique measuring absorption of near-infrared radiation by molecular bonds, enabling rapid, non-destructive identification and quantitative analysis of chemical and physical properties of materials.

 

 What this means for you:

 

  • Assess methods using NIR spectroscopy against the revised Ph. Eur. 2.2.40 requirements, particularly where NIR supports GMP identification, quantitative testing or process control
  • Check validation and lifecycle documentation: Ensure method qualification/validation, calibration models, reference datasets, instrument performance and ongoing model monitoring are adequately documented and scientifically justified
  • Perform a documented gap assessment

B) 2.2.47. Capillary electrophoresis (revised)

Capillary electrophoresis is an analytical separation technique in which charged molecules migrate through a narrow capillary under an electric field, separating according to electrophoretic mobility, principally charge, size and solution conditions.

 

 What this means for you:

 

  • A new section on hydrodynamic interaction has been added. In capillary electrophoresis, it can affect analyte movement and separation by altering local fluid flow and molecular mobility, particularly for larger molecules, particles or concentrated samples
  • A new section on electrokinetic injection has been added. This is a capillary electrophoresis sample-introduction technique in which an electric field drives charged analytes from the sample solution into the capillary

C) 2.6.27 Microbiological examination of cell-based preparations (new)

This new chapter explores the microbiological examination of cell-based preparations, taking into account the characteristics and limitations of these preparations.

 

 What this means for you:

 

  • The chapter states cell tests may not allow for the completion of conventional microbiological examination tests before administration to the patient
  • The chapter discusses limitations on sample quantities and sampling-related issues
  • The chapter discusses maintaining sterility if the sterility test cannot be performed

D) 2.6.39. Microbiological examination of human tissues (revised)

This chapter covers the selection of analytical procedures for the assessment of the microbiological quality of human tissue. The change is minor, with an emphasis that it does not relate to blood components. 

E) 2.4.24. Identification and control of residual solvents (revised)

This chapter describes the analytical procedures to be used to assess for residual solvents in pharmaceutical preparations. The changes appear primarily for the purposes of clarity. 

Monographs in revision

A) Water: Micro Determination

Ph. Eur. 2.5.32 describes coulometric Karl Fischer titration for determining small quantities of water, where iodine is generated electrochemically and consumption is proportional to water present.

The chapter is under review. The intended revision introduces dedicated instructions for:

  • The evaporation (oven) technique: Temperature, carrier gas flow rate and heating time
  • Clarifications on the operating principle and procedure, in particular the necessity to control the background drift, as well as the applicability of reference substances for either direct introduction or evaporation techniques

 

B) Vaccines

 

Ph. Eur. 2.6.16 describes tests for detecting extraneous infectious agents in human viral vaccines, assessing virus seed lots and production materials to demonstrate freedom from unintended contamination using specified biological and microbiological test systems.

This general chapter is being reviewed to take account of the revised ICH Q5A(R2) Guideline on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin.

Ph. Eur.00153 ‘Vaccines for Human Use’ is subject to a minor update, relating to establishing expiry dates.

 

C) Pharmaceutical preparations

 

Ph. Eur. 2619 provides a reference source of standards in the European Pharmacopoeia on active substances, excipients and dosage forms, which are to be applied in the manufacture/preparation of pharmaceuticals.

The chapter is being revised to differentiate between antimicrobial preservatives and stabilisers. 

 

How RSSL can support you

RSSL provides method development and validation, spectroscopic and chromatographic analytical techniques and microbiological analysis to support compliance with revised Ph. Eur. chapters. We also deliver GMP training and consultancy to help organisations implement updated compendial methods.

 

Section 2: FDA Guidance

The U.S. Food and Drug Administration (FDA) has issued further guidance relating to biosimilars entitled ‘Questions and Answers on Biosimilar Development and the BPCI Act’.

 

 What this means for you:

 

  • The guidance document provides answers to common questions regarding the Biologics Price Competition and Innovation Act of 2009 (BPCI Act)
  • The aim is to facilitate the development of proposed biosimilar and interchangeable biosimilar products

The document can be accessed here: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/questions-and-answers-biosimilar-development-and-bpci-act  

 

How RSSL can support you

RSSL provides biologics analytical support and ICH stability studies help manufacturers meet regulatory requirements across biosimilar development programmes.

 

Section 3: United States Pharmacopeia

Note: Access to the United States Pharmacopeia (USP) requires registration.

New chapters

There are several new USP chapters to be issued in April 2027. These are:

  • Pure Steam
  • Water for Injection

 

These two chapters have links to updated Total Organic Carbon (TOC) methodology and will have the option to use recombinant endotoxin testing reagents.

  • Sterile Water for Injection


This chapter has been updated for recombinant endotoxin reagents only.

 

  • Water for Pharmaceutical Purposes <1231>

 

This large chapter has had an extensive update. These cover risk assessment for ozone levels, the option to use recombinant endotoxin reagents, online TOC, microbial sample flushing volumes, TOC limits and calculations, nitrosamines added and microbial growth media.

 

  • Transportation Lane Temperature Mapping and Qualification <1079.5>

 

This is a new chapter that extends into what the MHRA define as ‘Good Distribution Practice’.

 

  • Biotechnology-Derived Articles—Isoelectric Focusing <1054>

 

The electrophoresis for protein separation is to be harmonised with the European Pharmacopeia.

 

  • Protein Determination <507>

 

The chapter update is for the addition of a third analytical method: Ultraviolet Light Absorbance under Variable Path Length.

 

  • Analysis of Biological Assays <1034> and Design and Development of Biological Assays <1032>

 

These are new chapters to support laboratory analytical development and testing.

 

 

USP chapters in development

 

 

A) 〈1664.5〉 Assessment of Leachables in Oral Drug Products

This is a proposed new chapter to addresses specific considerations for leachables in Oral Dosage Forms (ODFs), including liquids (solutions, suspensions, emulsions, elixirs and syrups), semisolids and pastes, and solids (tablets, capsules, pills, powders, granules and premixes). 

The chapter considers leachables from two sources - manufacturing systems used to produce the dosage form and container closure systems used to package the dosage form over its shelf life. 

 

 

B) Application of Technologies to Pharmaceutical Compounding - Process Validation

This text concerns the use of automation and technology in sterile compounding with respect to qualification, validation, verification and demonstration of non-inferiority.

C) Characterization of Apex Vessel Geometries and Irregularities

USP has issued stimuli to the revision process, aimed at early-stage chapter development. This concerns glass vessels used for pharmaceutical dissolution testing to eliminate or reduce drug coning (the accumulation of insoluble particles in the stagnant zone directly beneath the rotating paddle).

 

How RSSL can support you

How RSSL can support you RSSL supports compliance with updated USP requirements through method development, primary packaging and extractables and leachables testing and a range of analytical techniques including wet chemistry.

 

Section 4: MHRA Strategy 

 

The Medicines and Healthcare products Regulatory Agency (MHRA) has launched its strategy for 2027 - 2030. This sets out how the Agency is modernising regulation in response to rapid advances in science, technology and global healthcare. This includes an expansion in data collection, including real-world data from hospitals.

An introduction to the strategy can be found here: 


https://assets.publishing.service.gov.uk/media/6acf4903a57ddfe32196ac52/MHRA_Strategy_2030_HCP_explainer.pdf 

 

How RSSL can support you

RSSL delivers IRCA-accredited auditing training and GMP training courses to help organisations stay aligned with the MHRA's evolving inspection expectations.

 

Section 5: European Medicines Agency

 

The European Medicines Agency (EMA) has a draft Data Quality Framework (DQF) for EU medicines regulation consultation period open (running until 14th December 2026). This concerns the application to collection, management and submission of Adverse Drug Reaction reports.

This can be accessed here: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-data-quality-framework-dqf-eu-medicines-regulation-application-collection-management-submission-adverse-drug-reaction-reports_en.pdf 

 

How RSSL can support you

RSSL provides quality systems consultancy and regulatory training to support organisations strengthening data quality governance in line with evolving EMA requirements.

Need to contact us? Get help or ask us a question